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ABSTRACT
Primary liver cancer is one of the most common cancer in the world with highest cancer mortality rate. The most 
common type of primary liver cancer is hepatocellular carcinoma (HCC). There are many risk factors for liver cancer 
and currently available treatments for HCC are largely inadequate. Gene mutation and dysfunction of p53 are common 
and is recognized as an important molecular event in hepatocarcinogenesis. Therefore, replacement of the aberrant p53 
gene is an attractive approach in the treatment of HCC providing an alternative treatment for primary HCC. In this study, 
we assessed whether the transfection with wild-type p53 gene is able to restore the pro-apoptotic effects and evaluate 
the feasibility of gene therapy in fixing a faulty p53 molecule. We established a non-viral cationic lipid-based p53 gene 
delivery into two human HCC cell lines namely HLF and PLC/PRF/5 cells. Both cell lines have mutations in the p53 gene. 
We compared the results with the normal liver cell line, WRL68, that constitutively expresses the wild-type p53 gene. 
In this study, the introduction of wild-type p53 gene into HLF and PLC/PRF/5 cells resulted in an increased of p53 gene 
expression, protein expression and cells growth inhibition shown in MTS reduction cell viability assay, FITC-Annexin V 
and PI apoptosis assay, western blot and caspase activity assay. In summary, the study provides a promising therapeutic 
approach for p53 gene delivery into HCC patients. The p53 gene delivery can be instituted together with chemotherapy 
as a combination treatment to induce apoptosis.
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ABSTRAK
Kanser hati utama adalah salah satu kanser umum di dunia dengan kadar kematian kanser tertinggi. Jenis yang paling 
biasa untuk kanser hati utama adalah karsinoma  hepatosel (HCC). Terdapat banyak faktor risiko untuk kanser hati utama 
dan rawatan untuk HCC sebahagian besarnya tidak mencukupi. Mutasi gen dan kehilangan fungsi gen p53 adalah faktor 
yang paling biasa dan gen p53 diiktiraf sebagai antara rantaian molekul yang penting dalam proses pembentukan kanser 
hati. Oleh itu, pemulihan mutan gen p53 yang defektif adalah satu pendekatan yang menarik dalam rawatan HCC sebagai 
rawatan alternatif untuk HCC utama. Dalam kajian ini, penilaian dilakukan sama ada transfeksi gen p53 normal ke atas 
titisan sel HCC mampu mengembalikan kesan pro-apoptotik dan potensi terapi gen dalam pemulihan molekul p53 yang 
defektif. Ini melibatkan transfeksi gen p53 normal menggunakan teknik lipid kationik kepada dua jenis titisan sel HCC 
manusia iaitu HLF dan PLC/PRF/5. Kedua-dua jenis titisan sel ini mempunyai mutasi dalam gen p53. Keputusan kajian 
dibandingkan dengan titisan sel hati normal, WRL68, yang mengekspres gen p53 normal. Transfeksi gen p53 normal ke 
dalam titisan sel HLF dan PLC/PRF/5 menyebabkan peningkatan ekspresi gen p53, pertambahan ekspresi protein p53 dan 
perencatan pertumbuhan titisan sel-sel yang ditunjukkan dalam assai MTS sel pengurangan daya maju, assai apoptosis 
FITC-Annexin V & PI, pemendapan barat dan aktiviti caspase. Secara ringkasnya, kajian ini menyediakan pendekatan 
terapeutik yang boleh digunakan untuk menyalurkan gen p53 ke dalam sel pesakit HCC. Penyampaian gen p53 boleh 
dimulakan bersama dengan kemoterapi sebagai rawatan kombinasi untuk mendorong aktiviti apoptosis.
Kata kunci: Apoptosis; gen p53;  hepatosel karsinoma; titisan sel; transfeksi
INTRODUCTION
Primary liver cancer is the sixth most common cancer in 
the world with an estimate of 0.8 million people diagnosed 
annually (C.P 2014). It also accounts for one of the highest 
cancer mortality rates with 0.7 million deaths (9%) per 
year. The most common type of primary liver cancer is 
hepatocellular carcinoma (HCC). The major risk factors 
for liver cancer include chronic infection with hepatitis B 
and C (accounting for 54% and 31% of cases worldwide, 
respectively), the consumption of food contaminated 
with aflatoxin (produced by fungi which can contaminate 
food such as maize and nuts in tropical or sub-tropical 
countries) and heavy alcohol consumption (Chuang et 
al. 2009; Morgan et al. 2004; Parkin 2006; Shariff et 
al. 2009). The developing countries carry the biggest 
burden of liver cancer, with more than eight out of ten 
(84%) cases being diagnosed in 2008. In Malaysia, liver 
cancer is the fifth most common cancer in males and the 
1290 
tenth most common cancer in the population (Ministry of 
Health 2011). Currently, available treatments for HCC are 
largely inadequate and confined to surgical resection and 
liver transplantation. Chemotherapy and radiotherapy are 
potentially curative, however, these treatments are not 
universally applicable to all of HCC patients, especially for 
those with poor prognosis in which no effective therapy is 
available. Therefore, the development of novel therapeutic 
approaches for the treatment of HCC is urgently needed. 
Sunitinib, an oral multi-target receptor tyrosine kinase 
inhibitor and Brivanib, an oral inhibitor of fibroblast 
growth factor and VEGF pathway have both been shown 
to have some survival benefit in clinical trials (Cheng et 
al. 2009; Llovet et al. 2008; Park et al. 2011; Shariff et al. 
2009). However, patients treated with these drugs often 
developed progressive disease suggesting that there might 
be an alternative molecular pathway that drives the tumor 
progression. Another promising approach is using gene 
therapy and several genes have been targeted including a 
p53 gene (Li et al. 2011; Lu et al. 2008; Sakakima et al. 
2005; Senzer et al. 2013). 
 The p53 gene is a tumor suppressor gene found to 
be mutated in 80% of cancers (Algaba et al. 2003; de 
Moura Gallo et al. 2005; Naccarati et al. 2012; Ozdemir 
et al. 2010; Rivlin et al. 2011). Cancer cells with mutated 
or deficient p53 have been reported to be resistant to 
apoptosis (Ferraz da Costa et al. 2012; Rejeeth & Kannan 
2014; Wang et al. 2008) and this is common and an 
important molecular event in hepatocarcinogenesis. 
Therefore, replacement of the aberrant p53 gene is an 
attractive approach in the treatment of HCC. To date, various 
strategies of gene delivery have been used by researchers 
in either in vitro or in vivo studies. A clinical trial for HCC 
patients using E1B-deleted adenovirus was reported in 
2002, but the results showed minimal therapeutic effects 
(Habib et al. 2002), suggesting more effective vectors are 
needed to achieve a useful clinical impact. Following this, 
another clinical trial was conducted using recombinant 
adenovirus-p53 (rAd-p53 and trademarked as Gendicine) 
combined with fractionated stereotactic radiotherapy (fSRT) 
in the treatment of primary HCC (Yang et al. 2010). This 
combined treatment showed an overall good response 
rate compared to treatment with radiotherapy alone, with 
7 patients showing a complete response (35%), 10 partial 
response (50%) and 3 stable diseases (15%). The survival 
rates and disease-free survival rates of the combined 
therapy were also improved. The promising results of 
this study provide hope for an alternative treatment for 
primary HCC when the patients are inoperable or when 
the patients refuse operation. Many gene delivery studies 
employ the adenovirus as a vector due to its efficient gene 
transfer and high level of expression in a wide variety of 
cell types. However, there are safety concerns over the 
use of viral vectors. Although repeated administrations of 
adenovirus are possible, the gene transfer could become 
progressively less efficient. Also, there is a potential of 
replication competent virus generation. Above all, repeated 
administrations could result in the possibility of provoking 
an inflammatory response against the viral and transgene 
products in the patients. 
 Alternative strategies are by employing non-
viral vectors which include naked plasmid DNA, DNA 
complexed with cationic lipids and particles comprising 
DNA condensed with cationic polymers (Ferraz da Costa 
et al. 2012; Rejeeth & Kannan 2014; Wang et al. 2008). 
The advantages of non-viral vectors over their viral 
counterparts are that they have no limitation with regard to 
insert-size, they are less immunogenic and they are easier to 
produce. However, a major drawback of non-viral vectors 
is that the transfection is less efficient, although within an 
acceptable range, compared to the viral vectors.
 This study aimed to assess whether the transfection 
of wild-type p53 gene is able to restore the pro-apoptotic 
effects and evaluate the feasibility of gene therapy in fixing 
a faulty p53 molecule. We established a non-viral cationic 
lipid-based p53 gene delivery using the Lipofectamine™ 
2000 transfection reagent (Life Technologies, USA), into 
two human HCC cell lines namely HLF and PLC/PRF/5. Both 
cell lines have mutations in the p53 gene. PLC/PRF/5 carries 
the hotspot HCC mutation: G:C → T:A in codon 249 of exon 
7, while HLF carries the G:C → C:G transversion in codon 
244 of exon 7 (Hsu et al. 1993). We compared the results 
with the normal liver cell line, WRL68, that constitutively 
expresses the wild-type p53 gene.
METHODS
CELL LINES
The human HCC cell lines used in this study were HLF and 
PLC/PRF/5 cells. HLF cells were from an Asian patient while 
the PLC/PRF/5 cells were from a Caucasian. The selection 
of cell lines was to minimize the bias of geographical 
origin of cells.
CELL CULTURE
Both the HLF and PLC/PRF/5 cells were cultured according 
to the manufacturer’s recommendations (Japan Health 
Science Research Resources Bank and American Type 
Culture Collection, respectively). HLF was maintained in 
Dulbecco’s Modified Eagles Medium (DMEM) supplemented 
with 10% fetal calf serum (FCS), 20 mM HEPES, 20 mM 
sodium hydrogen carbonate, 2 mM L-glutamine, 100 
U/mL penicillin and 100 μg/mL streptomycin. PLC/
PRF/5 was cultured in Earl’s Modified Eagles Medium 
(EMEM) supplemented with 10% fetal calf serum (FCS), 
20 mM HEPES, 20 mM sodium hydrogen carbonate, 2 mM 
L-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, 
1 mM sodium pyruvate and 0.1 mM nonessential amino 
acids (NEAA). The normal liver cell line WRL68 was used 
as a control for the gene delivery experiments. WRL68 was 
cultured in Earl’s Modified Eagles Medium (EMEM) with 
supplementation as with PLC/PRF/5 but without sodium 
pyruvate. All the cell lines were maintained in a humidified 
atmosphere with 5% CO2 at 37°C. 
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PLASMIDS
The plasmid 11770:p53-GFP containing wild-type p53 
gene and tagged with GFP (Addgene, USA) was expanded 
in DH5α cells (Invitrogen, USA) and purified using the 
Plasmid Mini Kit (Qiagen, USA). The host plasmid, 
pEGFP-N1 (Addgene, USA) was used as a control. The 
plasmid was digested with restriction enzymes SalI and 
BamHI in reference to the vector map and was visualized 
by 1% agarose gel. 
WILD-TYPE p53 GENE TRANSFECTION
The transient transfections were performed using the 
Lipofectamine® 2000 Transfection Reagent and according 
to the manufacturer’s protocol (Life Technologies, USA). 
Cells were seeded a day before transfection at different 
densities according to the size of culture vessels and the 
respective assays; 1.5 × 104 cells for the 96-well plate in MTS 
assay and Caspase 3/7 assay; 5.0 × 105 cells for the 6-well 
plate for GFP quantification, FITC-Annexin V and Propidium 
Iodide (PI) double staining assay, RNA and protein 
extractions. On the following day, the culture medium was 
replaced and cells were treated with serum-free media with 
either plasmid p53-GFP complexed with LipofectamineÔ 
2000 transfection reagent or host plasmid complexed with 
LipofectamineÔ 2000 transfection reagent at a ratio 1:1. 
Untreated cells and cells treated with LipofectamineÔ 2000 
transfection reagent alone served as negative controls. 
Transfection was allowed to take place for 48 h and the 
cells were harvested, analyzed and assayed accordingly. 
SCORING OF GFP-POSITIVE CELLS
Transfection efficiency was scored and visualized 
by a confocal microscope (Leica TCS SP5 II, Leica 
Microsystems) at excitation wavelength 488 nm after 48 
h of transfection. Following this, transfected cells were 
quantified using the FACS Aria II(BD Biosciences, USA) and 
BD FACSDiva Software (Becton Dickinson, USA).
QUANTITATIVE REAL TIME-POLYMERASE CHAIN 
REACTION (QRT-PCR)
Total RNA was extracted from the transfected cell lines 48 
h post transfection using RNeasy Mini Kit (Qiagen, USA) 
according to the manufacturer’s instructions. The RNA 
concentrations were measured using a Bioanalyzer (Agilent 
2100, USA). First strand cDNA was synthesized using 
Reverse Transcription System (Bio-Rad, USA) according 
to manufacturer’s protocols. The qRT-PCR was performed 
using Rotor-Gene 600 (Corbett Lifescience, USA) and 
the p53 gene was amplified using the primer set for exon 
7 (171 bp): 5’-GGCCTCATCTTGGGCCTGTG-3’ and 
5’-CAGTGTGCAGGGTGGCAAGT-3’. b-actin (395 bp) 
was used as the housekeeping gene control and the primer 
set used was: 5’-AGGCTGTGCTGTCCCTGTATGC-3’ 
and 5’-ACCCAAGAAGGAAGGCTGGAAA-3’. 
Amplification was performed at an annealing temperature 
of 66°C. Experiments were done n triplicates. 
WESTERN BLOTTING ANALYSIS
All antibodies used in this study were purchased from Santa 
Cruz Biotechnology, USA unless stated otherwise. Total 
protein was extracted from the transfected cells 48 h post 
transfection using the RIPA lysis buffer. Following protein 
quantitation, proteins were separated on SDS-PAGE and 
transferred onto polyvinyl difluoride membrane according 
to standard methods. The membrane was blocked in Tris-
buffered saline containing skimmed milk prior to probing 
with primary antibodies against p53, p21 and b-actin 
(as a loading control) proteins. After serial washes with 
Tris-buffered saline, the membrane was incubated with 
horseradish peroxidase-conjugated secondary antibodies. 
Immunoreactive proteins were detected using an enhanced 
chemiluminescence system (ChemiDocTM Imaging 
System, Bio-Rad).
MTS REDUCTION CELL VIABILITY ASSAY
Cell viability was assessed using MTS CellTiter 96® 
Nonradioactive Cell Proliferation Assay according to the 
manufacturer’s protocol (Promega, USA). Briefly, cells 
were seeded in 96-well cell culture plates at 1 × 104 cells per 
well. After 48 h post-transfection, the medium was replaced 
and incubated with 20 uL with 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) reagent at 37°C for 4 h and absorbance 
was measured using a spectrophotometer at wavelength 
490 nm. All assays were performed in triplicate and 
repeated in three independent experiments.
FITC-ANNEXIN V AND PI APOPTOSIS ASSAY
48 h post-transfection, both attached and floating cells 
were collected, washed twice with PBS and stained with 
FITC-Annexin V Apoptosis Detection Kit (Sigma, USA) 
according to the manufacturer’s protocol. Basically, 5 μL 
of FITC-Annexin V conjugate and 10 μL of PI solution were 
added to each cell suspension, followed by incubation at 
room temperature for exactly 10 min and protected from 
light. After double supravital staining, the samples were 
immediately analyzed using FACS Aria II (BD Biosciences, 
USA) and BD FACSDiva Software (Becton Dickinson, USA). 
CASPASE ACTIVITY ASSAY
Following 48 h post transfection, the activities of caspase 
3 and 7 were measured using the Caspase-Glo® 3/7 Assay 
assay kit according to the manufacturer’s recommendation 
(Promega, Madison USA). Briefly, the plates containing 
cells were treated with 100 μL of Caspase-Glo and then 
gently mixed on a plate shaker at 300-500 rpm for 30 s. 
The plate was then incubated at room temperature for 
2 h. The luminescence of each sample was measured 
using a plate-reading luminometer (ThermoLabsystems, 
Thermo Fisher Scientific) with parameters of 1 min lag 
time and 0.5 s/well of read time. The experiments were 
performed in triplicates and repeated on two separate-
initiated cultures.
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STATISTICAL ANALYSIS
All the statistical analyses were performed using GraphPad 
Prism 7 and statistics significance was calculated by student 
t-test. A p<0.01 was considered statistically significant. 
RESULTS
PLASMID p53-GFP
The product of the correct size of approximately 5.9 kb 
was observed for undigested plasmid p53-GFP and single 
digestion with SalI or BamHI plasmid (Figure 1). The 
double digestions with SalI and BamHI showed plasmid 
vector backbone without p53-GFP with the size of ~4kb 
and p53-GFP gene size was ~2kb.
SCORING OF GFP-POSITIVE CELLS
Successfully transfected p53-GFP cells were visualization 
by a confocal microscope as green fluorescent cells due to 
the GFP protein that emits a signal at 488 nm. More than 
60% of liver cell lines were successfully transfected with 
p53-GFP (Figure 2). Further quantification of transfected 
cells by flow cytometer showed transfection efficiency 
were between 30.7 and 35.3% for every 10,000 cells 
(Figure 3). The results showed that we have optimized the 
transfection conditions.
ANALYSIS OF GENE EXPRESSION 
The results from qRT-PCR on the three liver cell lines were 
shown in Figure 4. There was more than one-fold increased 
in p53 expression observed in HLF and PLC/PRF/5 and only 
0.2-fold increased in WRL68 p53-transfected cells relative 
to null p53-transfected cells. 
ANALYSIS OF THE PROTEIN EXPRESSION 
The immunoblotting analysis (Figure 5) showed that the 
expression of p53 and p21 proteins was increased in both 
HLF and PLC/PRF/5 p53-transfected cells after 48 h of 
transfection in comparison to the non-transfected control 
cells. However, in the WRL68 p53-transfected cells, the 
FIGURE 1. Identification of plasmid 11770:  dp53-GFP (Addgene, USA). Digestion with restriction enzymes SalI and 
BamHI in reference to the vector map (1) 1kbp DNA ladder, (2) vector control (3), undigested plasmid, (4) single 
digestion with SalI, (5) single digestion with BamHI and (6) double digestion with SalI and BamHI. The undigested 
plasmid p53-GFP and single digestion plasmid showed the size of ~ 5.9kb as expected. The double digestion showed 
plasmid vector backbone without p53 GFP with the size of ~4kb and p53 GFP gene size was ~2kb
 A) HLF cell line B) PLC/PRF/5 C) WRL68
FIGURE 2. p53-GFP expression in liver cell lines (1) cells only under bright field filter, (2) cells transfected with only 
transfection reagent served as negative control under fluorescent filter, (3) transfected cells with p53-GFP under 
fluorescent filter and (4) overlap frame between (1) and (2). The view was taken under 10× magnification
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  FIGURE 3. Quantification of GFP transfection efficiency detected by flow cytometer in liver cell lines (1) cells only 
negative control, (2) cells and reagent negative control, (3) transfection with vector-GFP positive control and (4) 
transfection with p53-GFP. Percentage of transfection of efficiency are indicated, respectively
FIGURE 4. Quantification of exogenous p53 mRNA expression level following 48 h of transfection was 
measured by qRT-PCR. All expression levels are normalized to that of β-actin(housekeeping gene) in 
each well and are expressed as the fold increase for each sample relative to non-transfected control 
cells (cell only). This experiment was done in triplicates
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protein expression was observed to be relatively similar 
to non-transfected controls. The β-actin internal control 
was expressed in all the samples.
MTS REDUCTION CELL VIABILITY ASSAY
The HLF, PLC/PRF/5 and WRL68 p53-transfected cells had 
a 1.5-2.0-fold decrease in cell viability to compared to the 
non-transfected controls (Figure 6).
FITC-ANNEXIN V AND PI APOPTOSIS ASSAY 
The results of this assay were analyzed based on these 
quadrants; viable cells were FITC- Annexin V and PI 
negative; cells that were in early apoptosis were FITC-
Annexin V positive and PI negative; and cells that were 
in late apoptosis or already dead were both FITC-Annexin 
V and PI positive. All the three liver cell lines showed 
increased in early and late apoptosis cells compared to 
negative control cells (Figure 7, summarized in Table 1). 
The findings were comparable to the positive controls with 
induction with hydrogen peroxide.
CASPASE ACTIVITY ASSAY
Figure 8 shows an increase in the caspase 3 and caspase 
7 activity in HLF, PLC/PRF/5 and WRL68 p53-transfected 
cells as indicated by increased in luminescence reading as 
compared to controls. The findings are comparable to the 
positive control with induction with hydrogen peroxide.
DISCUSSION
In this study, the transfection efficiency analysis through 
confocal microscopy and flow cytometry showed 
some discrepancies in the results (Figures 2 & 3). The 
discrepancy in the results might be due to bias and number 
of cells per microscope field view. Quantification of p53-
GFP transfected cells using flow cytometry in a larger 
population of cells with a higher sensitivity represents 
more accurate data. The study has shown that the 
introduction of wild-type p53 into HLF and PLC/PRF/5 cells 
resulted in an increased in p53 gene expression, protein 
expression and cell growth inhibition possibly through 
apoptosis. This is in agreement with other published data 
FIGURE 6. MTS reduction assay. The cell viability was reduced to 40-50% in all 
three liver cells. This experiment was done in triplicates
FIGURE 5. Western Blot analysis of liver cell lines. Western blot analysis with anti-p53, anti-p21 and 
anti-β-actin antibodies. Total cell extracts were prepared from 1) cell only (non-transfected cells), 2) 
reagent control cells and 3) p53-GFP transfected cells. These cells were analyzed on Western blots 
and visualized using western blot imager (ChemiDocTM Imaging System, Bio-Rad)
p53
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FIGURE 7(C). FITC-Annexin V and PI Apoptosis assay on WRL68 cells (a) negative control cells only, 
(b) negative control reagent, (c) cells transfected with vector-GFP control, (d) positive control hydrogen 
peroxide and (E) cells transfected with p53-GFP
using other cancer cells (Ferraz da Costa et al. 2012; 
Lu et al. 2008; Shu et al. 2006). This also indicates 
that the presence of the mutant p53 protein is essential 
for the continuous growth and neoplastic behavior of 
cancer cells in HLF and PLC/PRF/5 cell lines. Cell growth 
inhibition of both HLF and PLC/PRF/5 cancer cells possibly 
via apoptosis by the wild-type p53 transfection was 
consistent in MTS reduction cell viability, FITC-Annexin 
V and PI apoptosis assay and Caspase activity assay. This 
might suggest the presence of mutant p53 expression and 
absence of wild-type p53 were not merely by chance but 
essential requirement for the progressive growth of the 
cancer cells carrying such mutations. The presence of 
p53 mutations due to the genetic changes as mentioned 
earlier affected the protein expression and downstream 
functional activity, thus abrogating the apoptosis process. 
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In the protein expression analysis, analysis of p21 protein 
was included because p53-mediated growth inhibition 
is dependent on induction of p21, which is an inhibitor 
of cyclin-dependent kinases that are required for cell 
cycle progression (He et al. 2005; Ravizza et al. 2004). 
Mutation of the p53 protein usually is associated with 
decreased p21 expression. The results showed that p53 
expression was in parallel with p21 expression suggest 
that possible apoptosis via p21/p53 pathways.
 In summary, we have established a transient non-
viral system of p53 gene inducible expression in which 
exogenous wild-type p53 gene could be delivered into 
cells, overexpressed and possibly restored the apoptotic 
effects. More extensive studies need to be carried out with 
stably transfected p53-GFP cell lines and effects together 
with chemotherapeutic drugs. However, this study 
provides a preliminary data and promising therapeutic 
approach for p53 gene delivery into HCC patients. In the 
future, the p53 gene delivery can be instituted together 
with chemotherapy as a combination treatment to induce 
apoptosis.
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